Stem definition | Drug id | CAS RN |
---|---|---|
calcium channel blockers, nifedipine derivatives | 674 | 167221-71-8 |
None
Property | Value | Reference |
---|---|---|
MRTD (Maximum Recommended Therapeutic Daily Dose) | 15.65 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
Vd (Volume of distribution) | 0.58 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 142 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.00 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 0.30 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Aug. 1, 2008 | FDA | MEDICINES CO |
None
None
None
None
Source | Code | Description |
---|---|---|
ATC | C08CA16 | CARDIOVASCULAR SYSTEM CALCIUM CHANNEL BLOCKERS SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS Dihydropyridine derivatives |
FDA CS | M0006414 | Dihydropyridines |
FDA MoA | N0000000069 | Calcium Channel Antagonists |
FDA EPC | N0000175421 | Dihydropyridine Calcium Channel Blocker |
MeSH PA | D002121 | Calcium Channel Blockers |
MeSH PA | D000077264 | Calcium-Regulating Hormones and Agents |
MeSH PA | D002317 | Cardiovascular Agents |
MeSH PA | D049990 | Membrane Transport Modulators |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Hypertensive disorder | indication | 38341003 | DOID:10763 |
Tachyarrhythmia | contraindication | 6285003 | |
Minimal change disease | contraindication | 44785005 | DOID:10966 |
Low blood pressure | contraindication | 45007003 | |
Pancreatitis | contraindication | 75694006 | DOID:4989 |
Heart failure | contraindication | 84114007 | DOID:6000 |
Hypertriglyceridemia | contraindication | 302870006 | |
Severe Aortic Valve Stenosis | contraindication |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 0.56 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Voltage-dependent L-type calcium channel subunit alpha-1C | Ion channel | BLOCKER | WOMBAT-PK | CHEMBL | |||||
Voltage-dependent L-type calcium channel subunit alpha-1D | Ion channel | BLOCKER | WOMBAT-PK | CHEMBL |
ID | Source |
---|---|
4028719 | VUID |
N0000178415 | NUI |
D08892 | KEGG_DRUG |
233603 | RXNORM |
4028719 | VANDF |
C0766108 | UMLSCUI |
CHEBI:135738 | CHEBI |
CHEMBL1237132 | ChEMBL_ID |
DB04920 | DRUGBANK_ID |
C118563 | MESH_SUPPLEMENTAL_RECORD_UI |
7468 | IUPHAR_LIGAND_ID |
7490 | INN_ID |
19O2GP3B7Q | UNII |
153994 | PUBCHEM_CID |
147455 | MMSL |
d07312 | MMSL |
012824 | NDDF |
439471002 | SNOMEDCT_US |
439624003 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Cleviprex | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10122-610 | EMULSION | 0.50 mg | INTRAVENOUS | NDA | 25 sections |
Cleviprex | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10122-610 | EMULSION | 0.50 mg | INTRAVENOUS | NDA | 25 sections |
Cleviprex | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10122-610 | EMULSION | 0.50 mg | INTRAVENOUS | NDA | 25 sections |
Cleviprex | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10122-611 | EMULSION | 0.50 mg | INTRAVENOUS | NDA | 25 sections |
Cleviprex | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10122-611 | EMULSION | 0.50 mg | INTRAVENOUS | NDA | 25 sections |
Cleviprex | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10122-611 | EMULSION | 0.50 mg | INTRAVENOUS | NDA | 25 sections |
Cleviprex | HUMAN PRESCRIPTION DRUG LABEL | 1 | 18124-011 | EMULSION | 0.50 mg | INTRAVENOUS | NDA | 29 sections |
Cleviprex | HUMAN PRESCRIPTION DRUG LABEL | 1 | 18124-011 | EMULSION | 0.50 mg | INTRAVENOUS | NDA | 29 sections |